Pure Biologics SA
WSE:PUR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.4852
9.9169
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Relative Value
The Relative Value of one PUR stock under the Base Case scenario is 0.02 PLN. Compared to the current market price of 4.54 PLN, Pure Biologics SA is Overvalued by 100%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
PUR Competitors Multiples
Pure Biologics SA Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| PL |
P
|
Pure Biologics SA
WSE:PUR
|
55.6m PLN | 0 | -3.2 | -6.1 | -6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 746 422.5 | -160 391.7 | -165 649.1 | -163 758.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
387.5B USD | 6.5 | 165 | 16 | 22.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.5B USD | 5.2 | 26.5 | 18.9 | 18.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
168.8B USD | 5.8 | 20.8 | 14.1 | 14.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD | 10.1 | 32.4 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 087.6 | -532.7 | -682 | -663.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 5.6 | 17.3 | 16.5 | 18.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87B AUD | 3.8 | 19.8 | 9.1 | 11.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR | 14 | 32.9 | 66.5 | 68.3 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.2B USD | 14.7 | 1 082.9 | 145.9 | 177 |
